Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

GUCY2C-targeted CAR-T immunotherapy

DRUG CLASS:

GUCY2C-targeted CAR-T immunotherapy

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

IM96 CAR-T cells (1)

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)

Mesothelin/GPC3/GUCY2C-CAR-T (0)

IM96 CAR-T cells (1)

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)

Mesothelin/GPC3/GUCY2C-CAR-T (0)

›

No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	GCC19CART Sensitive: B - Late Trials GCC19CART Sensitive : B	GCC19CART Sensitive: B - Late Trials GCC19CART Sensitive : B
GUCY2C expression	Colorectal Cancer	GUCY2C expression	Colorectal Cancer	IM96 CAR-T cells Sensitive: C3 – Early Trials IM96 CAR-T cells Sensitive : C3	IM96 CAR-T cells Sensitive: C3 – Early Trials IM96 CAR-T cells Sensitive : C3